176 related articles for article (PubMed ID: 36436020)
1. Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells.
Wang S; Zhang X; Zou X; Wen M; Gan C; Jiang X; Li M; Shen R; Zhu D; Yao A; Fang Y; Fox BA; Hu HM; Yu G; Wang X
Cancer Immunol Immunother; 2023 May; 72(5):1301-1313. PubMed ID: 36436020
[TBL] [Abstract][Full Text] [Related]
2. Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma.
Forget MA; Malu S; Liu H; Toth C; Maiti S; Kale C; Haymaker C; Bernatchez C; Huls H; Wang E; Marincola FM; Hwu P; Cooper LJ; Radvanyi LG
J Immunother; 2014; 37(9):448-60. PubMed ID: 25304728
[TBL] [Abstract][Full Text] [Related]
3. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
[TBL] [Abstract][Full Text] [Related]
4. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
5. 4-1BB Agonist Focuses CD8
Sakellariou-Thompson D; Forget MA; Creasy C; Bernard V; Zhao L; Kim YU; Hurd MW; Uraoka N; Parra ER; Kang Y; Bristow CA; Rodriguez-Canales J; Fleming JB; Varadhachary G; Javle M; Overman MJ; Alvarez HA; Heffernan TP; Zhang J; Hwu P; Maitra A; Haymaker C; Bernatchez C
Clin Cancer Res; 2017 Dec; 23(23):7263-7275. PubMed ID: 28947567
[No Abstract] [Full Text] [Related]
6. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
7. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid application.
Wang X; Dai Z; Lin X; Zou X; Wang R; Tasiheng Y; Yan Y; Ma M; Chen Y; Cheng H; Liu C; Yu X
Cancer Lett; 2024 Apr; 588():216741. PubMed ID: 38395378
[TBL] [Abstract][Full Text] [Related]
8. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
9. Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.
Wei T; Leisegang M; Xia M; Kiyotani K; Li N; Zeng C; Deng C; Jiang J; Harada M; Agrawal N; Li L; Qi H; Nakamura Y; Ren L
Oncoimmunology; 2021 May; 10(1):1929726. PubMed ID: 34104546
[TBL] [Abstract][Full Text] [Related]
10. Neoantigen-specific CD4
Hall MS; Teer JK; Yu X; Branthoover H; Snedal S; Rodriguez-Valentin M; Nagle L; Scott E; Schachner B; Innamarato P; Hall AM; Blauvelt J; Rich CJ; Richards AD; Ceccarelli J; Langer TJ; Yoder SJ; Beatty MS; Cox CA; Messina JL; Abate-Daga D; Mule JJ; Mullinax JE; Sarnaik AA; Pilon-Thomas S
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802604
[TBL] [Abstract][Full Text] [Related]
11. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
[No Abstract] [Full Text] [Related]
12. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
[TBL] [Abstract][Full Text] [Related]
13. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
14. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer.
Krishna S; Lowery FJ; Copeland AR; Bahadiroglu E; Mukherjee R; Jia L; Anibal JT; Sachs A; Adebola SO; Gurusamy D; Yu Z; Hill V; Gartner JJ; Li YF; Parkhurst M; Paria B; Kvistborg P; Kelly MC; Goff SL; Altan-Bonnet G; Robbins PF; Rosenberg SA
Science; 2020 Dec; 370(6522):1328-1334. PubMed ID: 33303615
[TBL] [Abstract][Full Text] [Related]
15. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
16. Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer.
Assadipour Y; Zacharakis N; Crystal JS; Prickett TD; Gartner JJ; Somerville RPT; Xu H; Black MA; Jia L; Chinnasamy H; Kriley I; Lu L; Wunderlich JR; Zheng Z; Lu YC; Robbins PF; Rosenberg SA; Goff SL; Feldman SA
Clin Cancer Res; 2017 Aug; 23(15):4347-4353. PubMed ID: 28377481
[No Abstract] [Full Text] [Related]
17. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
18. [Preclinical study of T cell receptor specifically reactive with
Cheng XJ; Jiang D; Zhang LH; Wang JH; Li YZ; Zhai JH; Yan BQ; Zhang LL; Xie XW; Li ZY; Ji JF
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):884-895. PubMed ID: 36241231
[TBL] [Abstract][Full Text] [Related]
19. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.
Wang QJ; Yu Z; Griffith K; Hanada K; Restifo NP; Yang JC
Cancer Immunol Res; 2016 Mar; 4(3):204-14. PubMed ID: 26701267
[TBL] [Abstract][Full Text] [Related]
20. Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement.
Friedman KM; Devillier LE; Feldman SA; Rosenberg SA; Dudley ME
J Immunother; 2011; 34(9):651-61. PubMed ID: 21989413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
